BCR and B-cell chronic lymphocytic leukemia: Entospletinib (GS-9973), like other classes of drugs inhibiting BCR signals, disrupts the cellular interactions with the tumor microenvironment and causes a redistribution of CLL cells, which clinically manifests by LN depletion and transient lymphocytosis (75).